Skip to main content
Wallace Bourgeois, MD, Pediatric Hematology & Oncology, Boston, MA

Wallace Bourgeois MD


Physician

Join to view full profile
  • 450 Brookline AveBoston, MA 02215

  • Phone+1 617-632-2423

  • Fax+1 617-632-6570

Dr. Bourgeois is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2018 - 2021
  • Boston Children’s Hospital/Boston Medical Center
    Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2018 - 2021
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2014 - 2018
  • New York University School of Medicine
    New York University School of MedicineClass of 2014

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2018 - 2028
  • NY State Medical License
    NY State Medical License 2015 - 2018
  • Pediatrics
    American Board of Pediatrics Pediatrics
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

Journal Articles

  • Health Care Utilization and Cost Among Pediatric Patients Receiving Unrelated Donor Allogeneic Hematopoietic Cell Transplantation  
    Diane George, Monica Bhatia, Prakash Satwani, James Garvin, Wallace Bourgeois, Nature

Grant Support

  • Characterizing and targeting acquired resistance to menin-KMT2A inhibitors in acute myeloid leukemia.DANA-FARBER CANCER INST2026–2031

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: